Top-News
Biotechnologie Dänemark

Bavarian Nordic AS Aktie

Aktie
WKN:  917165 ISIN:  DK0015998017 US-Symbol:  BVNKF
20,17 €
+0,57 €
+2,91%
23.04.25
Depot/Watchlist
Aktienanzahl *
78,12 Mio.
Marktkapitalisierung *
1,53 Mrd. €
Streubesitz
69,44%
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 25.06.2024
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,77: MK47SV
Werbung

Bavarian Nordic AS News

16.04.25 - GlobeNewswire
Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP)
Recommendation of first chikungunya vaccine for persons as young as 12 years old expands access for US travelers to regions with outbreak or elevated risk of chikungunya. ...
07.04.25 - Der Aktionär
Bavarian Nordic: Trotz Mpox‑Warnung – Aktie im Sinkflug
01.04.25 - Der Aktionär
Bavarian Nordic auf Achterbahnfahrt: Die Hintergründe!
31.03.25 - GlobeNewswire
Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine
COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-​dried ...
24.03.25 - BNP
Novo Nordisk, Freenet, Heidelberg Materials, Südzucker, Nasdaq, S&P 500 - Charttechnik mit Harald Weygand
Kommt die große Wende bei Nasdaq 100 und S&P 500? Und was ist im MSCI World los? – Darüber sprechen Harald Weygand und Holger Bosse in der Sendung Rendezvous mit ...
24.03.25 - BNP
Novo Nordisk, Freenet, Heidelberg Materials, Südzucker, Nasdaq, S&P 500 - Charttechnik mit Harald Weygand
Kommt die große Wende bei Nasdaq 100 und S&P 500? Und was ist im MSCI World los? – Darüber sprechen Harald Weygand und Holger Bosse in der Sendung Rendezvous mit ...
24.03.25 - BNP Paribas
Novo Nordisk, Freenet, Heidelberg Materials, Südzucker, Nasdaq, S&P 500 - Charttechnik mit Harald Weygand
Kommt die große Wende bei Nasdaq 100 und S&P 500? Und was ist im MSCI World los? – Darüber sprechen Harald Weygand und Holger Bosse in der Sendung Rendezvous mit ...
12.03.25 - GlobeNewswire
Bavarian Nordic A/S – Notice Convening Annual General Meeting
COPENHAGEN, Denmark, March 12, 2025 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual ...
07.03.25 - GlobeNewswire
Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older
COPENHAGEN, Denmark, March 7, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has ...
05.03.25 - GlobeNewswire
Bavarian Nordic Publishes Annual Report 2024
Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million. Two new early-​stage pipeline programs, Lyme disease and Epstein-​Barr Virus ...
28.02.25 - GlobeNewswire
Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older
First chikungunya vaccine approved in Europe for persons as young as 12 years old. On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, ...
25.02.25 - GlobeNewswire
Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine
Contract manufacturing agreement marks the first step in collaboration to establish supply for expanded access to chikungunya vaccines in low- and middle-​income countries. ...
17.02.25 - Der Aktionär
Bavarian Nordic: Zulassung – Valneva bekommt Konkurrenz
14.02.25 - GlobeNewswire
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older
First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers. On track for commercial ...
04.02.25 - Der Aktionär
Bavarian Nordic unter Druck: Darum wird die Aktie abgestraft
03.02.25 - GlobeNewswire
Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025
Travel Health business demonstrated strong growth of 22%. Additional mpox vaccine orders during outbreak drove higher revenues for the Public Preparedness business and also ...
31.01.25 - GlobeNewswire
Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older
First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old. The virus-​like particle (VLP) single-​dose chikungunya vaccine is expected to launch in ...
09.01.25 - GlobeNewswire
Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million
COPENHAGEN, Denmark, January 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a share buy-back program of up to DKK 150 million as announced on ...
04.01.25 - Boersia.de
Bavarian Nordic Aktie: Zukunftsweisende Unternehmensstrategien
Die dänische Impfstoffherstellerin Bavarian Nordic A/S verzeichnete in den vergangenen Wochen eine positive Entwicklung an der Börse. Der aktuelle Aktienkurs liegt bei 26,70 EUR ...
19.12.24 - Der Aktionär
Bavarian Nordic: Mpox‑Fälle in Deutschland – Details, Einschätzungen, Auswirkungen

Newssuche

Videos

newspaper
22.04.25 +1,37%
Technical Trading: US-​Anleihen Long bis September
10yr T-Notes Long Typ: Turbo Open End WKN: NG8ZZF Hebel: 14,89 Laufzeit: OpenEnd Einstieg: Market ... Mehr »